tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
Company profile
Ticker
TNXP
Exchange
Website
CEO
Seth Lederman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TAMANDARE EXPLORATIONS INC.
SEC CIK
Corporate docs
Subsidiaries
Tonix Pharmaceuticals, Inc. • Krele, LLC • Tonix Pharmaceuticals (Canada), Inc. • Tonix Pharma Holdings Limited • Tonix Pharma Limited • Jenner Institute LLC • Tonix R&D • Tonix Medicines, Inc. ...
IRS number
261434750
TNXP stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
8-K
Results of Operations and Financial Condition
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
424B5
Prospectus supplement for primary offering
29 Mar 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Regulation FD Disclosure
21 Mar 24
8-K
Regulation FD Disclosure
20 Mar 24
Latest ownership filings
4/A
SETH LEDERMAN
6 Mar 24
4
SETH LEDERMAN
29 Feb 24
4
BRADLEY SAENGER
29 Feb 24
4
JESSICA EDGAR MORRIS
29 Feb 24
4
GREGORY M SULLIVAN
29 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13G
Empery Asset Management, LP
11 Jan 24
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.92 mm | 7.92 mm | 7.92 mm | 7.92 mm | 7.92 mm | 7.92 mm |
Cash burn (monthly) | 5.98 mm | 11.03 mm | 9.38 mm | 10.31 mm | 7.80 mm | 8.50 mm |
Cash used (since last report) | 43.49 mm | 80.17 mm | 68.22 mm | 75.00 mm | 56.68 mm | 61.78 mm |
Cash remaining | -35.58 mm | -72.25 mm | -60.31 mm | -67.09 mm | -48.76 mm | -53.87 mm |
Runway (months of cash) | -5.9 | -6.6 | -6.4 | -6.5 | -6.3 | -6.3 |
Institutional ownership, Q3 2023
9.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 8 |
Closed positions | 6 |
Increased positions | 5 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.84 bn |
Total shares | 8.31 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 4.50 mm | $0.00 |
Armistice Capital | 1.45 mm | $790.25 mm |
Sabby Management | 1.25 mm | $679.87 mm |
Vanguard | 398.15 k | $216.99 mm |
Renaissance Technologies | 223.91 k | $122.00 k |
Geode Capital Management | 126.30 k | $68.85 mm |
CVI Investments | 111.25 k | $75.00 k |
VIRT Virtu Financial | 66.99 k | $37.00 k |
BLK Blackrock | 48.36 k | $26.36 mm |
STT State Street | 31.21 k | $17.01 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Feb 24 | Lederman Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 1,309,911 | 0.00 | 1,309,911 |
27 Feb 24 | Lederman Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 1,903,680 | 875.69 k | 1,903,680 |
27 Feb 24 | Lederman Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 0.368 | 235,320 | 86.60 k | 235,320 |
27 Feb 24 | Saenger Bradley | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 282,000 | 129.72 k | 282,000 |
27 Feb 24 | Saenger Bradley | Stock Option Common Stock | Grant | Acquire A | No | No | 0.368 | 282,000 | 103.78 k | 282,000 |
27 Feb 24 | Morris Jessica Edgar | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 317,000 | 145.82 k | 317,000 |
27 Feb 24 | Morris Jessica Edgar | Stock Option Common Stock | Grant | Acquire A | No | No | 0.368 | 317,000 | 116.66 k | 317,000 |
27 Feb 24 | Sullivan Gregory M | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 358,000 | 164.68 k | 358,000 |
27 Feb 24 | Sullivan Gregory M | Stock Option Common Stock | Grant | Acquire A | No | No | 0.368 | 358,000 | 131.74 k | 358,000 |
8 May 23 | Treco James | Stock Option Common Stock | Grant | Acquire A | No | No | 0.509 | 60,000 | 30.54 k | 60,000 |
News
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
11 Apr 24
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
1 Apr 24
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
1 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Press releases
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
24 Apr 24
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
1 Apr 24
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
28 Mar 24
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
25 Mar 24
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
29 Feb 24